| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
03-26-2013, 06:02 PM
|
#1 | |||
|
||||
|
Member
|
Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting
A new levodopa product (ODM-101) developed by Orion Corporation could improve the treatment of advanced Parkinson's disease patients. According to a Phase II study, presented yesterday at American Academy of Neurology's Annual Meeting in San Diego, ODM-101 significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias compared to reference product Stalevo®, which is an established standard medication for advanced Parkinson's patients experiencing so-called end-of-dose wearing off symptoms associated with levodopa therapy http://www.orion.fi/en/News-and-medi...rchive/2013/3/
__________________
Sim00 Born in 1969, diagnosed PD in 2007, first symptoms 2004. DBS in July 2016. |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Positive results of new levodopa product for Parkinson's disease | Parkinson's Disease | |||
| More Neuropathy in Levodopa-Treated Parkinson's Patients | Parkinson's Disease | |||
| NP201: Product candidate for the continuous symptomatic treatment of Parkinson's dise | Parkinson's Disease | |||
| Rotigotine As Levodopa Adjunct Is Effective In Advanced Parkinson's Disease | Parkinson's Disease | |||
| Caffeine Aids Levodopa in Some Parkinson's Patients | Parkinson's Disease | |||
A new levodopa product could improve the treatment of advanced Parkinson's patients
Linear Mode
